Evidence map›Paper›PMID 39259423›Full record

ReviewAdvances in experimental medicine and biology2025

Atrophic Macular Degeneration and Stem Cell Therapy: A Clinical Review.

Silvia Babighian, Maria Sole Zanella, Irene Gattazzo, Alessandro Galan, Caterina Gagliano, Fabiana D'Esposito, Marco Zeppieri

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Silvia BabighianDepartment of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, Padova, Italy.
Maria Sole ZanellaDepartment of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, Padova, Italy.
Irene GattazzoDepartment of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, Padova, Italy.
Alessandro GalanDepartment of Ophthalmology, Ospedale Sant'Antonio, Azienda Ospedaliera, Padova, Italy.
Caterina GaglianoEye Clinic Catania University San Marco Hospital, Catania, Italy.
Fabiana D'EspositoImperial College Ophthalmic Research Group (ICORG) Unit, Imperial College, London, UK.
Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, Udine, Italy. mark.zeppieri@asufc.sanita.fvg.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is one of the leading causes of visual loss in older patients. No effective drug is available for this pathology, but studies about therapy with stem cells replacing the damaged retinal cells with retinal pigment epithelium (RPE) were described. The documentation of AMD progression and the response to stem cell therapy have been performed by optical coherence tomography, microperimetry, and other diagnostic technologies.This chapter reports a clinical review of the most important clinical trials and protocols regarding the use of stem cells in AMD.

Indexed as

Macular DegenerationStem Cell TransplantationClinical Trials as TopicHumansRetinal Pigment EpitheliumTomography, Optical CoherenceAge-related macular degeneration (AMD)Optical coherence tomographyRetinal pigment epithelium (RPE)Vascular endothelial growth factor (VEGF)

Identifiers

PMID39259423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.